Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCTXW
Upturn stock ratingUpturn stock rating

BriaCell Therapeutics Corp (BCTXW)

Upturn stock ratingUpturn stock rating
$0.13
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: BCTXW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Year Target Price $

Year Target Price $

Analyst’s Price TargetsFor last 52 week
$Target price
Low$0.02
Current$0.13
high$0.7

Analysis of Past Performance

Type Stock
Historic Profit -90.6%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 48.08M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.72
52 Weeks Range 0.02 - 0.70
Updated Date 06/18/2025
52 Weeks Range 0.02 - 0.70
Updated Date 06/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -131.54%
Return on Equity (TTM) -688.17%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 5776754
Shares Outstanding -
Shares Floating 5776754
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

BriaCell Therapeutics Corp

stock logo

Company Overview

overview logo History and Background

BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for cancer. Founded with the goal of harnessing the power of the immune system to fight cancer, BriaCell has focused on novel approaches to stimulate the immune system to recognize and eliminate cancer cells. While specific founding year information isn't publicly and widely available, the company has been active in clinical trials and research for several years.

business area logo Core Business Areas

  • Oncology Immunotherapy: Development of immunotherapies for advanced solid tumors, specifically focused on stimulating the immune system to target and eliminate cancer cells.
  • Bria-IMTu2122 Platform: The company's main immunotherapy platform technology.

leadership logo Leadership and Structure

BriaCell's leadership team consists of experienced professionals in the fields of oncology, immunology, and drug development. Specific details on the organizational structure may vary and are subject to change, reflecting the needs of a growing biotechnology company.

Top Products and Market Share

overview logo Key Offerings

  • Bria-IMTu2122: Bria-IMTu2122 is BriaCell's lead investigational product, a targeted immunotherapy for advanced breast cancer. The therapy works by stimulating the patient's immune system to recognize and kill cancer cells. Since BriaCell is still in the clinical trial stage, it currently has no revenues. Competitors include major pharmaceutical companies like Roche (RHHBY), Merck (MRK), and Bristol-Myers Squibb (BMY) that have approved immunotherapies.

Market Dynamics

industry overview logo Industry Overview

The oncology immunotherapy market is experiencing substantial growth, driven by advancements in understanding the immune system's role in fighting cancer. The area is highly competitive and research-intensive with multiple players focusing on different types of immunotherapies.

Positioning

BriaCell focuses on a specific niche within the immunotherapy market, aiming to develop targeted immunotherapies for advanced cancers. Their competitive advantage lies in their unique approach to stimulate a broad and effective immune response against cancer cells.

Total Addressable Market (TAM)

The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. BriaCell is positioned to potentially capture a portion of this market with successful clinical trial results and regulatory approvals for its Bria-IMTu2122 platform.

Upturn SWOT Analysis

Strengths

  • Novel immunotherapy platform (Bria-IMTu2122)
  • Targeted approach for advanced cancers
  • Experienced management team focused on oncology and immunology

Weaknesses

  • Limited financial resources compared to major pharmaceutical companies
  • Product is still in the clinical trial phase
  • Reliance on successful clinical trial outcomes

Opportunities

  • Positive clinical trial data leading to regulatory approval
  • Partnerships with larger pharmaceutical companies
  • Expansion of Bria-IMTu2122 platform to other cancer types
  • Increased funding through grants or investments

Threats

  • Failure to achieve positive clinical trial results
  • Competition from established immunotherapies
  • Regulatory hurdles and delays
  • Changes in the healthcare reimbursement landscape

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • RHHBY

Competitive Landscape

BriaCell faces intense competition from established pharmaceutical companies with extensive resources and approved immunotherapies. Its advantage lies in its unique approach, while its disadvantage stems from limited resources and the need to prove clinical efficacy.

Growth Trajectory and Initiatives

Historical Growth: BriaCell's growth has been marked by the progress of its Bria-IMTu2122 platform through clinical trials.

Future Projections: Future growth depends heavily on the success of ongoing and planned clinical trials. Analyst projections, if available, are based on the potential market opportunity and probability of success for Bria-IMTu2122.

Recent Initiatives: Recent initiatives include ongoing clinical trials for Bria-IMTu2122, expansion of the research team, and efforts to secure additional funding.

Summary

BriaCell Therapeutics is a high-risk, high-reward biotech company focused on cancer immunotherapy. The company's future hinges on the successful development and commercialization of its Bria-IMTu2122 platform. While its novel approach presents an opportunity, it faces significant challenges from larger, well-established competitors and the inherent uncertainties of clinical trials. BriaCell needs to secure adequate funding and demonstrate positive clinical data to realize its potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • ClinicalTrials.gov
  • Various financial news sources

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change. Investing in biotechnology companies involves significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BriaCell Therapeutics Corp

Exchange NASDAQ
Headquaters West Vancouver, BC, Canada
IPO Launch date 2021-02-24
CEO, President & Director Dr. William V. Williams FCPA, M.D.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.